Menu
GeneBe

KMT2A

lysine methyltransferase 2A, the group of PHD finger proteins|SET domain containing|Zinc fingers CXXC-type|Lysine methyltransferases|Bromodomain containing

Basic information

Region (hg38): 11:118436455-118526832

Previous symbols: [ "MLL" ]

Links

ENSG00000118058NCBI:4297OMIM:159555HGNC:7132Uniprot:Q03164AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • Wiedemann-Steiner syndrome (Definitive), mode of inheritance: AD
  • Wiedemann-Steiner syndrome (Supportive), mode of inheritance: AD
  • Wiedemann-Steiner syndrome (Definitive), mode of inheritance: AD
  • Wiedemann-Steiner syndrome (Strong), mode of inheritance: AD
  • Wiedemann-Steiner syndrome (Definitive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Wiedemann-Steiner syndromeADGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingCraniofacial; Dermatologic; Musculoskeletal; Neurologic22795537; 25810209

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the KMT2A gene.

  • not provided (1887 variants)
  • Wiedemann-Steiner syndrome (239 variants)
  • Inborn genetic diseases (135 variants)
  • not specified (36 variants)
  • KMT2A-related condition (20 variants)
  • Intellectual disability (11 variants)
  • See cases (9 variants)
  • Neurodevelopmental disorder (5 variants)
  • Autism spectrum disorder (4 variants)
  • Kabuki syndrome 1 (2 variants)
  • Adrenal cortex carcinoma (1 variants)
  • Intellectual disability;Hirsutism (1 variants)
  • Autism;Intellectual disability (1 variants)
  • intellectual deficiency (1 variants)
  • Language disorder (1 variants)
  • Rare genetic intellectual disability (1 variants)
  • Cornelia de Lange syndrome 1 (1 variants)
  • Neurodevelopmental delay;Bilateral ptosis;Atypical behavior (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the KMT2A gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
7
clinvar
422
clinvar
30
clinvar
459
missense
11
clinvar
31
clinvar
934
clinvar
80
clinvar
29
clinvar
1085
nonsense
81
clinvar
16
clinvar
2
clinvar
99
start loss
1
clinvar
1
frameshift
144
clinvar
30
clinvar
1
clinvar
175
inframe indel
2
clinvar
25
clinvar
3
clinvar
30
splice donor/acceptor (+/-2bp)
17
clinvar
12
clinvar
1
clinvar
30
splice region
2
22
42
2
68
non coding
1
clinvar
99
clinvar
49
clinvar
149
Total 253 91 972 604 108

Highest pathogenic variant AF is 0.00000702

Variants in KMT2A

This is a list of pathogenic ClinVar variants found in the KMT2A region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
11-118436513-A-T Wiedemann-Steiner syndrome Uncertain significance (Mar 03, 2022)2433171
11-118436526-G-C Uncertain significance (May 06, 2022)1312973
11-118436538-T-G KMT2A-related disorder Likely pathogenic (Oct 07, 2022)2637324
11-118436539-C-A Inborn genetic diseases Uncertain significance (Jul 08, 2022)2294976
11-118436543-G-A Wiedemann-Steiner syndrome Uncertain significance (Apr 07, 2022)2442180
11-118436560-C-T Likely benign (Jul 19, 2022)1613775
11-118436563-G-GGGC Uncertain significance (Jan 03, 2024)3010406
11-118436566-C-T Likely benign (Jan 30, 2024)754854
11-118436570-G-A Uncertain significance (Jun 13, 2022)1415052
11-118436575-C-T Likely benign (Jul 17, 2023)2066490
11-118436575-CG-C Wiedemann-Steiner syndrome Likely pathogenic (Mar 23, 2021)1343266
11-118436577-G-C Uncertain significance (May 24, 2023)2642416
11-118436581-G-A Likely benign (Nov 11, 2023)722262
11-118436581-G-C Likely benign (Aug 10, 2021)1535104
11-118436590-C-A Likely benign (May 01, 2021)1555823
11-118436594-G-A Uncertain significance (Jul 12, 2023)2742776
11-118436594-G-T not specified Uncertain significance (Oct 03, 2023)1363232
11-118436594-GGGGGCGCCCCGCGGCAACGCGTCCCGGCCCTGCTGCTTCCCCCCGGGCCCCCGGTCGGCGGTGGCGGCCCC-G Likely pathogenic (Aug 01, 2021)1298527
11-118436597-G-T Uncertain significance (Aug 14, 2023)2797050
11-118436601-C-G not specified Benign/Likely benign (Jan 31, 2024)158711
11-118436601-C-T Uncertain significance (Jan 25, 2021)1469158
11-118436605-G-A Likely benign (Aug 24, 2022)2026903
11-118436606-C-A Likely benign (Aug 04, 2023)2737246
11-118436615-G-A Uncertain significance (Oct 28, 2023)2168186
11-118436617-C-T Likely benign (Jul 01, 2022)1630897

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
KMT2Aprotein_codingprotein_codingENST00000534358 3690335
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
1.005.43e-231257340131257470.0000517
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense6.2312712.07e+30.6150.00011225808
Missense in Polyphen49910420.4788912874
Synonymous2.246887670.8970.00004108159
Loss of Function11.451610.03110.00001031919

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00002900.0000290
Ashkenazi Jewish0.000.00
East Asian0.00005440.0000544
Finnish0.000.00
European (Non-Finnish)0.00007940.0000791
Middle Eastern0.00005440.0000544
South Asian0.00003280.0000327
Other0.0001640.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Histone methyltransferase that plays an essential role in early development and hematopoiesis. Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac). In the MLL1/MLL complex, it specifically mediates H3K4me, a specific tag for epigenetic transcriptional activation (PubMed:12453419, PubMed:20677832, PubMed:26886794). Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity (PubMed:19187761, PubMed:26886794). Has no activity toward histone H3 phosphorylated on 'Thr-3', less activity toward H3 dimethylated on 'Arg-8' or 'Lys-9', while it has higher activity toward H3 acetylated on 'Lys-9'. Binds to unmethylated CpG elements in the promoter of target genes and helps maintain them in the nonmethylated state (PubMed:20010842). Required for transcriptional activation of HOXA9 (PubMed:12453419, PubMed:20677832, PubMed:20010842). Promotes PPP1R15A-induced apoptosis. Plays a critical role in the control of circadian gene expression and is essential for the transcriptional activation mediated by the CLOCK-ARNTL/BMAL1 heterodimer. Establishes a permissive chromatin state for circadian transcription by mediating a rhythmic methylation of 'Lys-4' of histone H3 (H3K4me) and this histone modification directs the circadian acetylation at H3K9 and H3K14 allowing the recruitment of CLOCK-ARNTL/BMAL1 to chromatin (By similarity). {ECO:0000250|UniProtKB:P55200, ECO:0000269|PubMed:10490642, ECO:0000269|PubMed:12453419, ECO:0000269|PubMed:15960975, ECO:0000269|PubMed:19187761, ECO:0000269|PubMed:19556245, ECO:0000269|PubMed:20010842, ECO:0000269|PubMed:26886794, ECO:0000305|PubMed:20677832}.;
Disease
DISEASE: Wiedemann-Steiner syndrome (WDSTS) [MIM:605130]: A syndrome characterized by hairy elbows (hypertrichosis cubiti), intellectual disability, a distinctive facial appearance, and short stature. Facial characteristics include long eyelashes, thick or arched eyebrows with a lateral flare, and downslanting and vertically narrow palpebral fissures. {ECO:0000269|PubMed:22795537}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Chromosomal aberrations involving KMT2A are a cause of acute leukemias. Translocation t(1;11)(q21;q23) with MLLT11/AF1Q; translocation t(3;11)(p21;q23) with NCKIPSD/AF3p21; translocation t(3,11)(q25,q23) with GMPS; translocation t(4;11)(q21;q23) with AFF1/MLLT2/AF4; insertion ins(5;11)(q31;q13q23) with AFF4/AF5Q31; translocation t(5;11)(q12;q23) with AF5-alpha/CENPK; translocation t(6;11)(q27;q23) with AFDN; translocation t(9;11)(p22;q23) with MLLT3/AF9; translocation t(10;11)(p11.2;q23) with ABI1; translocation t(10;11)(p12;q23) with MLLT10/AF10; t(11;15)(q23;q14) with KNL1 and ZFYVE19; translocation t(11;17)(q23;q21) with MLLT6/AF17; translocation t(11;19)(q23;p13.3) with ELL; translocation t(11;19)(q23;p13.3) with MLLT1/ENL; translocation t(11;19)(q23;p23) with GAS7; translocation t(X;11)(q13;q23) with FOXO4/AFX1. Translocation t(3;11)(q28;q23) with LPP. Translocation t(10;11)(q22;q23) with TET1. Translocation t(9;11)(q34;q23) with DAB2IP. Translocation t(4;11)(p12;q23) with FRYL. Fusion proteins KMT2A-MLLT1, KMT2A- MLLT3 and KMT2A-ELL interact with PPP1R15A and, on the contrary to unfused KMT2A, inhibit PPP1R15A-induced apoptosis. {ECO:0000269|PubMed:10490642}.; DISEASE: Note=A chromosomal aberration involving KMT2A may be a cause of chronic neutrophilic leukemia. Translocation t(4;11)(q21;q23) with SEPT11. {ECO:0000269|PubMed:10490642}.;
Pathway
Cushing,s syndrome - Homo sapiens (human);Lysine degradation - Homo sapiens (human);Transcriptional misregulation in cancer - Homo sapiens (human);Histone Modifications;Senescence and Autophagy in Cancer;Gene expression (Transcription);Generic Transcription Pathway;PKMTs methylate histone lysines;RNA Polymerase II Transcription;RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function;Chromatin modifying enzymes;Chromatin organization;RUNX1 regulates transcription of genes involved in differentiation of HSCs;Transcriptional regulation by RUNX1 (Consensus)

Recessive Scores

pRec
0.489

Intolerance Scores

loftool
rvis_EVS
-3.35
rvis_percentile_EVS
0.41

Haploinsufficiency Scores

pHI
0.580
hipred
Y
hipred_score
0.728
ghis
0.603

Essentials

essential_gene_CRISPR
E
essential_gene_CRISPR2
essential_gene_gene_trap
K
gene_indispensability_pred
gene_indispensability_score

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Kmt2a
Phenotype
homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; craniofacial phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; skeleton phenotype; renal/urinary system phenotype; hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; neoplasm; embryo phenotype;

Zebrafish Information Network

Gene name
kmt2a
Affected structure
nucleate erythrocyte
Phenotype tag
abnormal
Phenotype quality
absent

Gene ontology

Biological process
transcription by RNA polymerase II;apoptotic process;positive regulation of transporter activity;circadian regulation of gene expression;embryonic hemopoiesis;histone H4-K16 acetylation;regulation of megakaryocyte differentiation;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;histone H3-K4 methylation;positive regulation of histone H3-K4 methylation;protein-containing complex assembly;regulation of histone H3-K14 acetylation;histone H3-K4 trimethylation;regulation of hematopoietic stem cell differentiation;negative regulation of DNA methylation;regulation of histone H3-K9 acetylation;positive regulation of cellular response to drug
Cellular component
nucleus;nucleoplasm;cytosol;histone methyltransferase complex;MLL1 complex
Molecular function
RNA polymerase II distal enhancer sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;AT DNA binding;DNA-binding transcription factor activity;protein binding;zinc ion binding;histone-lysine N-methyltransferase activity;histone methyltransferase activity (H3-K4 specific);identical protein binding;protein homodimerization activity;transcription regulatory region DNA binding;unmethylated CpG binding;lysine-acetylated histone binding